PhD Scholarship Opportunities

The Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE) is currently inviting scholarship applications from suitable domestic/international candidates for two exciting PhD projects based at the University of Newcastle, Australia and Hunter Medical Research Institute (HMRI).

____________________________________________________________________

‘Drug-Drug Interactions and Cannabis Medicines’

This project will address the clinical question of if, and how prescribed cannabis medicines interact with other prescribed medications.

Cannabis contains many different cannabinoids of which Tetrahydrocannabinol (THC) and Cannabidiol (CBD) have received the most attention. These drugs are reported to be mainly eliminated via metabolism involving CYP450 and UGT enzyme systems. Patients taking cannabis medicines are likely to be co-administered many different medications. Currently there is a paucity of data on potential drug-drug interactions between cannabinoids and commonly used medications. Additionally, few if any data are available on the metabolism of other cannabinoids present in cannabis beyond THC and CBD. This project will investigate metabolism of various cannabinoids using in vitro and in vivo studies to identify potentially significant drug-drug interactions of cannabinoids with other commonly prescribed medications. The project is situated within the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), a National Health and Medical Research Council Centre of Research Excellence, the first federally-funded centre for medicinal cannabis research and the University of Newcastle's Centre for Human Drug Research.

supervisors

Dr Peter Galettis; Associate Professor Jennifer Schneider; Professor Jennifer Martin

Funding

$27,596 per annum (2019 rate) indexed annually. For a PhD candidate, the living allowance scholarship is for 3.5 years and the tuition fee scholarship is for four years.

further information

For further information, including Eligibility Criteria and How to Apply please visit the University of Newcastle’s webpage for this opportunity.

Applications close 1 November, 2019.

 

 

 

____________________________________________________________________

'Brain Cancer and Cannabinoids'

Intensive studies of cannabinoids in brain cancer to enable rapid uptake into practice.

Glioblastoma (GBM) is a rapidly progressive brain tumour. It is usually treated by surgery followed by radiotherapy and chemotherapy. GBM has a very poor two year survival rate of less than 20% related to drug resistance both that is innate and which develops, in combination with the development of a micro-environment that protects the GBM cells from being killed. Our team have recently summarised the brain cancer biology that causes this treatment resistance and highlighted the important role in preventing or targeting resistance development during treatment by exploring combination therapies, new drugs or appropriate use of repurposed therapies, and considerations of the complicated immune environment of the brain cancer. Importantly, some of the derivatives of the Cannabis plant (cannabinoids) have recently shown to decrease cell growth and increases cell death of human GBM cells. The evidence for cannabinoids in brain cancer suggests exploring their benefit in humans is appropriate. This work needs to begin with appropriate selection of the type of cannabinoid, dose, and relationship to timing of chemotherapy and radiation for brain cancer. This study will aim to provide important information on cannabinoid dosing, timing with regards to chemotherapy, radiotherapy and route of administration efficacy and safety in GBM, and will examine if one of a suite of medical cannabinoid products can improve survival rates. The project is situated within the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), a National Health and Medical Research Council Centre of Research Excellence, the first federally-funded centre for medicinal cannabis research and the University of Newcastle's Centre for Human Drug Research.

supervisors

Associate Professor Nikola Bowden; Dr Peter Galettis; Professor Jennifer Martin

Funding

$27,596 per annum (2019 rate) indexed annually. For a PhD candidate, the living allowance scholarship is for 3.5 years and the tuition fee scholarship is for four years.

further information

For further information, including Eligibility Criteria and How to Apply please visit the University of Newcastle’s webpage for this opportunity.

Applications close 1 November, 2019.

____________________________________________________________________

ABOUT US

The Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE) has been established through the National Health and Medical Research Council (NHMRC) Centre of Research Excellence scheme. It draws together over twenty Australian research leaders and clinicians from major national universities and research institutions to establish a research evidence base to inform safe clinical use of medicinal cannabinoids and to guide policy as cannabinoids are introduced into therapeutic practice in Australia.

ACRE • All Right Reserved

Website by mudbath